Abstract
Tazobactam/piperacillin (TAZ/PIPC) was administered to one patient with sepsis and 6 patients suspected to have sepsis. The underlying diseases were acute leukemia (4 patients), malignant lymphoma (2 patients) and myelodysplastic syndrome (1 patient). The drug was administered through intravenous drip infusion at 5.0 g/day, divided into two doses, for 4-9 days. The clinical response was excellent in 2 patients, good in one, fair in one and poor in 3. We observed eruption in one patient, and slight elevation of GOT and GPT in 2 patients.
